Figures & data
FIG. 1 HPLC chromatograms demonstrating the amount of OTC dissolved inside the reverse micelles as a function of incubation time. The peak area standing for OTC rises with ongoing incubation.
FIG. 2 Changes in the magnitude of reverse micellar solubilization of OTC as a function of incubation time (hr). The OTC/CTAB/water/ethyl formate compositions (mg/mg/ml/ml) were ˆ = 20/20/0.2/3, □ = 20/20/0.4/3, and ▵ = 10/20/0.2/3.
FIG. 3 Effect of OTC quantity on its encapsulation efficiency. OTC (10 to 40 mg) was dissolved in the CTAB (20 mg)/water (0.2 ml)/ethyl formate (3 ml) reverse micelles, and microspheres were prepared by use of 0.6 g PLGA75:25.
FIG. 4 Effect of PLGA75:25 quantity on OTC encapsulation efficiency. Various amounts of PLGA75:25 were dissolved in the OTC (20 mg)/CTAB (20 mg)/water (0.2 ml)/ethyl formate (3 ml) reverse micelles to prepare microspheres. An increase in PLGA75:25 content enhances its encapsulation efficiency.
FIG. 5 Dependence of OTC encapsulation efficiency on the amount of water used to prepare reverse micelles. The amounts of OTC, CTAB, ethyl formate, and PLGA75:25 used in this experiment were 20 mg, 20 mg, 3 ml, and 0.6 g, respectively.
FIG. 6 SEM micrographs illustrate the external and internal morphology of PLGA75:25 microspheres prepared by the reverse micellar encapsulation process. The microspheres have spherical surface, and their internal matrices are free of hollow cavities.
